Welcome to LookChem.com Sign In|Join Free

CAS

  • or

42461-84-7

Post Buying Request

42461-84-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

42461-84-7 Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 42461-84-7 differently. You can refer to the following data:
1. dental carries prophylactic
2. Flunixin meglumine has been used as a nonsteroidal anti-inflammatory drug standard in electrospray ionization mass spectrometry (LC-ESI/MS).
3. Cyclooxigenase inhibitor. Anti-inflammatory; analgesic; antipyretic.

Definition

ChEBI: An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic propert es; used in veterinary medicine for treatment of horses, cattle and pigs.

Brand name

Banamine Veterinary (Schering-Plough Animal Health).

General Description

Flunixin meglumine is a nonsteroidal anti-inflammatory drug and a potent cyclo-oxygenase (COX) inhibitor. It is commonly used as an analgesic and antipyretic in animals.Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Biological Activity

flunixin meglumine serves as a non-narcotic and non-steroidal analgesic agent with antipyretic activities. as a potent inhibitor of the enzyme cyclooxygenase, flunixin meglumine has demonstrated a wide-spectrum of biological activities including anti-inflammation and pain-alleviating. moreover, flunixin meglumine could be applied as a drug in animals for the management of intestinal ischaemia, colic, and endotoxemia. [1]

Biochem/physiol Actions

COX1, COX2 and PLA2 inhibitor non-narcotic analgesic, anti-pyretic, anti-inflammatory.

Veterinary Drugs and Treatments

In the United States, flunixin meglumine is approved for use in horses, cattle and swine; however, it is approved for use in dogs in other countries. The approved indications for its use in the horse are for the alleviation of inflammation and pain associated with musculoskeletal disorders and alleviation of visceral pain associated with colic. In cattle it is approved for the control of pyrexia associated with bovine respiratory disease and endotoxemia, and control of inflammation in endotoxemia. In swine, flunixin is approved for use to control pyrexia associated with swine respiratory disease. Flunixin has been suggested for many other indications in various species, including: Horses: foal diarrheas, shock, colitis, respiratory disease, post-race treatment, and pre- and post ophthalmic and general surgery; Dogs: disk problems, arthritis, heat stroke, diarrhea, shock, ophthalmic inflammatory conditions, pre- and post ophthalmic and general surgery, and treatment of parvovirus infection; Cattle: acute respiratory disease, acute coliform mastitis with endotoxic shock, pain (downer cow), and calf diarrheas; Swine: agalactia/hypogalactia, lameness, and piglet diarrhea. It should be noted that the evidence supporting some of these indications is equivocal and flunixin may not be appropriate for every case.

in vitro

an in vitro whole blood model in feedlot calves was adopted to detect the activity of the anti-inflammatory agents flunixin-meglumine (flu), rs (±) carprofen (cpf) and s (+) cpf. the drugs all exhibited inhibitory activity on coxs, with an order of flu > s (+) cpf > rs (±) cpf in their potency. this finding indicated that flu was a nonselective suppressorr of bovine coxs, whereas rs (±) cpf and s (+) cpf selectively inhibited cox-2 isoenzyme. [2]

in vivo

findings from mice, rats and monkeys suggested flunixin meglumine as a potent non-narcotic analgesic agent after parenteral administration. after being subcutaneous administered, this agent showed higher efficacy than pentazocine, meperidine and codeine in the rat yeast paw test. intramuscular administration and subcutaneous administration of flunixin meglumine had similar effects. moreover, orally administered flunixin meglumine also exerted analgesic and anti-inflammatory activities. based on mice abdominal constriction test, flunixin meglumine had comparable efficacy to pentazocine and was more potent than meperidine and codeine. in primates, 10 mg/kg flunixin meglumine showed an equal efficacy to that of 0.3 mg/kg morphine. [1]

IC 50

a potent cyclooxygenase inhibitor with ic50 values of 1 nm.

references

[1]ciofalo vb, latranyi mb, patel jb and taber ri. flunixin meglumine: a non-narcotic analgesic. j pharmacol exp ther. 1977 mar; 200(3): 501-7.[2]miciletta m, cuniberti b, barbero r and re g. in vitro enantioselective pharmacodynamics of carprofen and flunixin-meglumine in feedlot cattle. j vet pharmacol ther. 2014 feb; 37(1): 43-52. [3] jochle w, moore jn, brown j, baker gj, lowe je, fubini s, reeves mj, watkins jp and white na. comparison of detomidine, butorphanol, flunixin meglumine and xylazine in clinical cases of equine colic. equine vet j suppl. 1989 jun; (7): 111-6.

Check Digit Verification of cas no

The CAS Registry Mumber 42461-84-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,2,4,6 and 1 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 42461-84:
(7*4)+(6*2)+(5*4)+(4*6)+(3*1)+(2*8)+(1*4)=107
107 % 10 = 7
So 42461-84-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H11F3N2O2.C7H17NO5/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12;1-8-2-4(10)6(12)7(13)5(11)3-9/h2-7H,1H3,(H,18,19)(H,20,21);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

42461-84-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (PHR1442)  Flunixin Meglumine  pharmaceutical secondary standard; traceable to USP, PhEur

  • 42461-84-7

  • PHR1442-1G

  • 791.15CNY

  • Detail
  • Sigma-Aldrich

  • (Y0000443)  Flunixin meglumine  European Pharmacopoeia (EP) Reference Standard

  • 42461-84-7

  • Y0000443

  • 1,880.19CNY

  • Detail
  • USP

  • (1274607)  Flunixin meglumine  United States Pharmacopeia (USP) Reference Standard

  • 42461-84-7

  • 1274607-300MG

  • 4,326.66CNY

  • Detail
  • Sigma

  • (F0429)  Flunixin meglumine  ≥98% (HPLC)

  • 42461-84-7

  • F0429-100MG

  • 1,208.61CNY

  • Detail
  • Sigma

  • (F0429)  Flunixin meglumine  ≥98% (HPLC)

  • 42461-84-7

  • F0429-500MG

  • 4,861.35CNY

  • Detail

42461-84-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name flunixin meglumine

1.2 Other means of identification

Product number -
Other names 2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid meglumine salt Banamine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:42461-84-7 SDS

42461-84-7Downstream Products

42461-84-7Relevant articles and documents

Preparation method of flunixin meglumine

-

Paragraph 0022; 0025; 0038-0041; 0046-0053, (2019/01/24)

The invention discloses a preparation method of flunixin meglumine the preparation method, and the method specifically comprises the following steps: (1) adding 2-chloronicotinic acid and 2-methyl-3-trifluoromethyl aniline into a sodium hydroxide water solution for stirring, adding ethylene glycol as well as a phase transfer catalyst and p-toluenesulfonic acid and copper oxide, controlling the temperature and time, adjusting the pH value of the solution, stirring, standing, layering, stirring, filtering, washing filter cake, and drying to obtain flunixin; and (2) reacting the flunixin obtainedin the step (1) with N-methylglucosamine in isopropyl alcohol, and meanwhile, adding a filler; carrying out heating reflux, filtering, cooling, stirring and crystallizing, carrying out crystal suction filtration, and washing crystals with isopropanol to obtain the flunixin meglumine. The preparation method of the flunixin meglumine is convenient and simple in operation, the reflecting efficiencyis high, the reaction temperature is low, the reaction time is short, and the cost is low; moreover, the prepared flunixin meglumine is high in purity and high in yield.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 42461-84-7